Home » Newsletters » BioWorld Science

BioWorld Science

April 8, 2016

View Archived Issues

Bayer Schering Pharma divulges factor XIa inhibitors

Changzhou Yinsheng Pharmaceutical and Sichuan University patent HCV NS4B inhibitors

Jiangsu Carefree, Nanjing Carephar and Nanjing Carephar Shenghui report JAK inhibitors

Intra-Cellular Therapies discloses PDE1B inhibitors

FORMA Therapeutics introduces isocitrate dehydrogenase inhibitors

UChicago and Evelo Biosciences sign agreement to develop cancer therapy

Ironwood reports first-in-human results for cardiovascular disease candidate IW-1973

FDA accepts IND application for Adaptimmune affinity enhanced T-cell therapy targeting AFP

Immunovaccine and Leidos to collaborate on a Zika virus vaccine candidate

Pfizer and IBM to develop remote monitoring system for Parkinson's disease patients

Juno Therapeutics and Wuxi AppTec start new cell therapy-focused company in China

Galapagos begins phase IIa study of GLPG-1690 in IPF

New biomarker panel described for Hirschprung disease

S100-A4 overexpression shows promise as a prognostic biomarker for signet-ring cell carcinoma

Cynata Therapeutics's MSC product shows promising results in murine model of GvHD

Two of Volition Rx's blood-based biomarker assays receive CE Mark

Large, multinational studies of anti-HIV antibody VRC-01 launched by NIH

E.U. approves subcutaneous formulation of epoetin alfa product Binocrit for nephrology use

Cardiac MyBP-C is a highly senstitive biomarker of myocardial injury

FDA places clinical hold on IONIS-TTRRx study

IMT-001, an immunotherapy for the treatment of early-onset type 1 diabetes

AstraZeneca and Lilly announce continuation of pivotal Alzheimer's disease trial

FDA committee recommends accelerated approval of Ocaliva

DURECT announces changes in phase III trial PERSIST

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...